The Truveta Genome Project, Regeneron Genetics Center, and Illumina are working with lots of health systems, representing thousands of people, to format the exomes of their first ten million individuals. The health systems stated in Truveta’s news on Monday that their partnership may aid in the development of next-generation data analytics to improve diagnoses, increase the efficacy of clinical trials, and promote a more equal coming in medical. This is part of what may be the largest and most diverse sequencing project of genotypic and phenotypic information ever assembled. ” This is the database the world needs now”, Erik Wexler, president and CEO of Providence, said in a video statement that accompanied the news. Working with 30 health systems that represent a different cross-section of U.S. people, Truveta stated that its goal is to establish a solid foundation for analytics that support community health management initiatives, promote the development of novel treatments and therapies, and address issues relating to barriers to health equity. According to the news, dominant health system leaders from across the country will receive individual consent to use biospecimens from lab tests linked to their de-identified electronic health records for anonymized biological research. They will take them to RGC for genomic sequencing, where all de-identifiable data will be added to Truveta Data, which employs the Truveta Language Model. Built on Microsoft Azure, the large-language, multi-modal unnatural knowledge design changes billions of data points with standardization, Truveta said. The regulatory-grade information is updated daily and is available as a reference for biotech and scientific researchers working to improve the prevention, diagnosis, and treatment of diseases. The information may increase the effectiveness of clinical trials by identifying patient groups that are most likely to respond to particular treatments, lower costs, and increase success rates. According to Truveta, Leftover biospecimens will also be kept in order to assist potential multi-omics sequencing by living technology companies studying community exome information. ” With nearly three million exomes sequenced at RGC to date, Regeneron experts have already identified dozens of genetic-based drug target for a wide range of problems– including chronic liver disease, obesity, cancer and neurodegenerative conditions – that have led to many clinical-stage solutions”, Dr. Aris Baras, senior vice president at Regeneron and head of the RGC, said in a statement. ” As we continue to scale our genomics initiatives, we seek more targets and medicines, while expanding the potential impact of our research to optimize clinical trials and personalize healthcare delivery”, he explained. We believe that this valuable information, which could fuel personalized care, personalized treatments, and opportunities for disease prevention, could be the cure for cancer, Wexler said in the statement. We conducted scientifically rigorous research on data for over 120 million patients in four years to advance healthcare for all. With the aid of AI and tens of millions of records to inform our research into how genetic factors impact our health, we can develop custom treatments based on a patient’s distinctive genetic makeup, said Eugene Woods, CEO of Advocate Health. ” In other words, we can help more people get healthy and stay healthy”. According to Wright Lassiter III, CEO of CommonSpirit Health,” We hope to deepen our understanding of the ways that particular groups are uniquely affected by their environments or other factors and develop targeted approaches to prevent and treat illness.” Henry Ford Health’s CEO, Bob Riney, noted that participating in the genome project demonstrates the organization’s commitment to innovation as well as “delivering the highest standard of care to those we serve.” ” The Truveta Genome Project has the potential to transform healthcare from treating disease to preventing disease, and we are excited to make it happen”, Michael Dowling, CEO of Northwell Health, said. THE LARGER TREND In order to mine existing datasets and uncover new insights at scale, fourteen major health systems joined forces in 2021 to launch Truveta, a Seattle-based data-driven precision medicine and population health platform. ” We have a unique opportunity today to rebuild the health care system in our country, so it is better, stronger, and more responsive to the needs of everyone – especially the vulnerable and underserved populations”, Lloyd Dean, now chief executive emeritus of CommonSpirit Health, said at the time. Later that year, Truveta and Microsoft collaborated to expand the use of Azure-based AI and security tools to improve the reach of its population health analytics. This latest endeavor builds on a previously announced strategic investment by 17 health systems, Illumina and Regeneron, Truveta said. Each of us can use the project to” contain untold secrets to significantly advance the discovery of the science of humanity, promoting the well-being of our families and communities, and lowering the cost of care,” said Terry Myerson, CEO and founder of Truveta, in a statement. ” This collaboration underscores our dedication to improving patient care and advancing value-based care initiatives, ultimately transforming how diseases are understood, prevented, diagnosed and cured”, added Jason Graefe, corporate vice president of ISV and digital natives for Microsoft Corp. Andrea Fox is senior editor of Healthcare IT News.
Email: afox@himss.org
Healthcare IT News is a HIMSS Media publication.
Trumpeta and 30 other health systems increase the goal of genetic sequencing
